Physician profile
Jodean C Lapointe
NPI 1851955819
$5,258.73
in general payments reported to CMS, 2019-2025
48 companies · $1,472 in 2025
The $1,472 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.71 · 2022: $125 · 2023: $1,795 · 2024: $1,773 · 2025: $1,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,890 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,890.39 |
| Education | $148.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $969.79 | 2023 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $300.66 | 2023-2025 | Calquence, Enhertu, Tagrisso |
| Karyopharm Therapeutics INC. | $245.26 | 2023-2024 | Xpovio |
| Janssen Biotech, INC. | $236.34 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Daiichi Sankyo INC. | $232.08 | 2023-2025 | Enhertu, Vanflyta |
| Novartis Pharmaceuticals Corporation | $213.12 | 2023-2025 | |
| Eisai INC. | $207.02 | 2024-2025 | |
| Gilead Sciences, INC. | $203.22 | 2023-2025 | Trodelvy |
| Astellas Pharma US INC | $186.23 | 2023-2025 | Padcev |
| Merck Sharp & Dohme LLC | $151.79 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $151.26 | 2024 | Reblozyl, Pomalyst, Opdualag |
| Morphosys, US INC. | $139.52 | 2023 | Monjuvi |
| Seagen INC. | $139.47 | 2022-2023 | Adcetris |
| Bayer Healthcare Pharmaceuticals INC. | $136.05 | 2021-2024 | |
| Genzyme Corporation | $135.80 | 2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $134.23 | 2024 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $133.72 | 2023-2025 | Ninlaro, Fruzaqla, Iclusig |
| Jazz Pharmaceuticals INC. | $91.53 | 2024-2025 | |
| Caris Mpi, INC. | $89.14 | 2025 | Mi Cancer Seek |
| Cti Biopharma Corp. | $88.86 | 2023 | Vonjo |
| Tempus Ai, INC | $77.48 | 2024 | |
| Genentech USA, INC. | $70.01 | 2024-2025 | Phesgo, Polivy, Lunsumio |
| Abbvie INC. | $64.82 | 2024-2025 | |
| Tersera Therapeutics LLC | $61.79 | 2024-2025 | Zoladex |
| Glaxosmithkline, LLC. | $61.45 | 2023-2025 | Ojjaara |
| Invivyd INC | $59.73 | 2025 | Pemgarda |
| Immunocore Limited | $56.86 | 2024-2025 | Kimmtrak |
| Beigene USA, INC. | $49.47 | 2023-2025 | Brukinsa, Tevimbra |
| Servier Pharmaceuticals LLC | $44.63 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $44.00 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $40.06 | 2024-2025 | Qinlock, Romvimza |
| Coherus Oncology, INC. | $38.50 | 2024 | |
| Incyte Corporation | $37.37 | 2024 | Jakafi, Monjuvi |
| Pfizer INC. | $36.27 | 2025 | |
| Boston Scientific Corporation | $35.83 | 2025 | Wavewriter Alpha Prime 16 |
| Regeneron Healthcare Solutions, INC. | $34.23 | 2024 | Libtayo |
| Agios Pharmaceuticals, INC. | $34.02 | 2024-2025 | Pyrukynd |
| Sobi, INC | $26.83 | 2025 | |
| Adc Therapeutics America, INC. | $25.67 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $25.36 | 2023 | Epkinly, Imbruvica |
| Stemline Therapeutics INC. | $21.64 | 2025 | Orserdu |
| Beone Medicines USA, INC. | $21.35 | 2025 | Brukinsa |
| Adaptive Biotechnologies Corporation | $19.64 | 2024 | Clonoseq |
| E.R. Squibb & Sons, L.L.C. | $18.25 | 2024 | Eliquis |
| Lilly USA, LLC | $17.97 | 2024 | Verzenio, Jaypirca, Retevmo |
| Sumitomo Pharma America, INC. | $17.58 | 2025 | Orgovyx |
| Springworks Therapeutics, INC. | $16.93 | 2024 | Ogsiveo |
| Pharmaessentia USA Corporation | $15.90 | 2024 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodean Lapointe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.